We are live on !
Find out more
Affinity Asset Advisors Portfolio holdings
AUM
$2.21B
Turnover
29.69%
1-Year Est. Return
431.26%
This Fund
S&P 500
This Quarter Est. Return
+29.83%
1 Year Est. Return
+431.26%
3 Year Est. Return
+1,487.3%
5 Year Est. Return
+3,318.95%
10 Year Est. Return
–
AUM
$2.21B
AUM Growth
+$276M
(+14%)
Cap. Flow
-$34.2M
Cap. Flow % of AUM
Cap. Flow %
-1.55%
Top 10 Holdings %
Top 10 Hldgs %
39.41%
Holding
128
New
23
Increased
32
Reduced
32
Closed
15
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.8
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Tracks Biotherapeutics
TRAX
|
+$38M |
| 2 |
Roivant Sciences
ROIV
|
+$28.1M |
| 3 |
Avalo Therapeutics
AVTX
|
+$24.6M |
| 4 |
Revolution Medicines
RVMD
|
+$21.9M |
| 5 |
Insmed
INSM
|
+$20.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.6M |
| 2 |
Arcellx
ACLX
|
+$41.7M |
| 3 |
Teva Pharmaceutical Industries Limited
TEVA
|
+$34.2M |
| 4 |
Terns Pharmaceuticals
TERN
|
+$29.7M |
| 5 |
Apogee Therapeutics
APGE
|
+$26.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.73% |
| 2 | Miscellaneous | 9.21% |
| 3 | Financials | 1.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Rezolute
RZLT
$373M
| $5.2M | 0.24% |
1,000,000
-547,641
| -35% | -$2.03M |
2024 Q1
9 quarters
|
|
77
Precision BioSciences
DTIL
$187M
| $5.08M | 0.23% |
646,576
+48,630
| +8% | +$342K |
2026 Q1
1 quarter
|
|
78
Hemab Therapeutics
COAG
$1.63B
| $5.07M | 0.23% |
+138,030
| New | +$3.81M |
2026 Q2
0 quarters
|
|
79
Viridian Therapeutics
VRDN
$2.59B
| $4.59M | 0.21% |
250,000
| – | – |
2024 Q2
8 quarters
|
|
80
ArriVent BioPharma
AVBP
$947M
| $4.34M | 0.2% |
125,000
-50,000
| -29% | -$1.48M |
2025 Q4
2 quarters
|
|
81
Verrica Pharmaceuticals
VRCA
$65.8M
| $4.33M | 0.2% |
707,338
| – | – |
2025 Q4
2 quarters
|
|
82
Compass Pathways
CMPS
$1.61B
| $4.26M | 0.19% |
301,183
-807,300
| -73% | -$8.19M |
2025 Q3
3 quarters
|
|
83
MBX Biosciences
MBX
$2.43B
| $4.14M | 0.19% |
75,000
-75,000
| -50% | -$2.62M |
2025 Q3
3 quarters
|
|
84
Research Alliance Corp III
RACC
$92.2M
| $3.96M | 0.18% |
+370,000
| New | +$3.86M |
2026 Q2
0 quarters
|
|
85
Immunovant
IMVT
$6.01B
| $3.85M | 0.17% |
100,000
| – | – |
2025 Q3
3 quarters
|
|
86
Amanat Acquisition Corp
AMAN
$98.9M
| $3.81M | 0.17% |
+375,000
| New | +$3.79M |
2026 Q2
0 quarters
|
|
87
Biohaven
BHVN
$2.22B
| $3.72M | 0.17% |
+250,000
| New | +$2.69M |
2026 Q2
0 quarters
|
|
88
Faeth Therapeutics
FTH
$519M
| $3.61M | 0.16% |
+144,404
| New | +$3.34M |
2026 Q2
0 quarters
|
|
89
Karyopharm Therapeutics
KPTI
$12.4M
| $3.05M | 0.14% |
312,500
-187,500
| -38% | -$1.63M |
2025 Q4
2 quarters
|
|
90
Alector
ALEC
$204M
| $3.04M | 0.14% |
1,510,000
+1,010,000
| +202% | +$2.16M |
2026 Q1
1 quarter
|
|
91
SpyGlass Pharma
SGP
$944M
| $2.93M | 0.13% |
131,586
-118,414
| -47% | -$2.57M |
2026 Q1
1 quarter
|
|
92
DELISTED
Crinetics Pharmaceuticals
CRNX
| $2.81M | 0.13% |
75,000
| – | – |
2023 Q3
11 quarters
|
|
93
Oaktree Acquisition Corp III Life Sciences Unit
OACCU
$195M
| $2.75M | 0.12% |
250,000
| – | – |
2024 Q4
6 quarters
|
|
94
JATT II Acquisition Corp
JATT
$80.3M
| $2.27M | 0.1% |
+200,000
| New | +$2.13M |
2026 Q2
0 quarters
|
|
95
Neumora Therapeutics
NMRA
$76.2M
| $1.82M | 0.08% |
+1,070,651
| New | +$2.04M |
2026 Q2
0 quarters
|
|
96
Amylyx Pharmaceuticals
AMLX
$3.59B
| $1.78M | 0.08% |
+98,999
| New | +$1.53M |
2026 Q2
0 quarters
|
|
97
Adlai Nortye Group ADS
ANL
$681M
| $1.77M | 0.08% |
153,847
-10,901
| -7% | -$133K |
2026 Q1
1 quarter
|
|
98
Spruce Biosciences
SPRB
$132M
| $1.62M | 0.07% |
+30,000
| New | +$1.68M |
2026 Q2
0 quarters
|
|
99
CALL
Summit Therapeutics
SMMT
$12.4B
| $1.46M | 0.07% |
+100,000
| New | +$1.77M |
2026 Q2
0 quarters
|
|
100
Eikon Therapeutics
EIKN
$446M
| $1.28M | 0.06% |
+98,001
| New | +$1M |
2026 Q2
0 quarters
|
|
Similar funds
Affinity Asset Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Affinity Asset Advisors held 128 positions worth $2.21B, up 14% from $1.94B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Affinity Asset Advisors's Q2 2026 filing shows 23 new, 32 increased, 32 reduced and 15 closed positions. Its largest new stake was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M. The largest sale was Centessa Pharmaceuticals, an estimated $55.6M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier, followed by Miscellaneous and Financials.
- Affinity Asset Advisors's largest Q2 2026 buy was First Tracks Biotherapeutics: 2,032,012 shares worth $40.9M.
- Affinity Asset Advisors added most to Roivant Sciences in Q2 2026, an estimated $28.1M increase.
- Affinity Asset Advisors's biggest Q2 2026 reduction was Teva Pharmaceutical Industries Limited, cutting an estimated $34.2M.
- Affinity Asset Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $55.6M.
- Affinity Asset Advisors's ten largest holdings make up 39% of its $2.21B portfolio in Q2 2026.
- Affinity Asset Advisors opened 23 new positions and closed 15 in Q2 2026.
- Affinity Asset Advisors's portfolio value rose 14% quarter-over-quarter to $2.21B.
Based on Affinity Asset Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.